Maurizio Poggi
Overview
Explore the profile of Maurizio Poggi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Stasi V, La Sala D, Cozzi R, Scavuzzo F, De Geronimo V, Poggi M, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941803
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, providing a groundbreaking therapeutic option for patients with various advanced-stage cancers. While these treatments can significantly extend survival, they also carry a substantial...
2.
Chiloiro S, Appetecchia M, Bianchi A, Costa D, De Acetis C, Gargiulo P, et al.
Drugs Context
. 2024 May;
13.
PMID: 38817802
Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the...
3.
Basile M, Valentini I, Attanasio R, Cozzi R, Persichetti A, Samperi I, et al.
Glob Reg Health Technol Assess
. 2024 Jan;
11:1-16.
PMID: 38230389
Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or...
4.
Cozzi R, Auriemma R, De Menis E, Esposito F, Ferrante E, Iati G, et al.
Endocr Metab Immune Disord Drug Targets
. 2023 May;
23(12):1459-1479.
PMID: 37171003
Introduction: This guideline (GL) is aimed at providing a reference for the management of prolactin (PRL)-secreting pituitary adenoma in adults. However, pregnancy is not considered. Methods: This GL has been...
5.
Chiloiro S, Costa D, Lauretta R, Mercuri V, Sbardella E, Samperi I, et al.
Endocrine
. 2022 Aug;
78(2):343-353.
PMID: 35986839
Introduction: Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in...
6.
Casale M, Baldini M, Del Monte P, Gigante A, Grandone A, Origa R, et al.
Recenti Prog Med
. 2022 Aug;
113(9):495-554.
PMID: 35939846
Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding research area; therefore, recommendations supporting the appropriateness of treatments are a pressing need for the medical community. Methods: The...
7.
Maggio R, Messina F, DArrigo B, Maccagno G, Lardo P, Palmisano C, et al.
Front Endocrinol (Lausanne)
. 2022 Jul;
13:873189.
PMID: 35784576
New radioimaging techniques, exploiting the quantitative variables of imaging, permit to identify an hypothetical pathological tissue. We have applied this potential in a series of 72 adrenal incidentalomas (AIs) followed...
8.
Casale M, Baldini M, Del Monte P, Gigante A, Grandone A, Origa R, et al.
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407442
Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding research area; therefore, recommendations supporting the appropriateness of treatments are a pressing need for the medical community. Methods: The...
9.
Cozzi R, Ambrosio M, Attanasio R, Battista C, Bozzao A, Caputo M, et al.
Eur J Endocrinol
. 2022 Jan;
186(3):P1-P33.
PMID: 35000899
Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different clinical settings and always require an individually tailored approach. This is the reason why a panel of Italian...
10.
Monti S, Presciuttini F, Deiana M, Motta C, Mori F, Renzelli V, et al.
Thyroid
. 2021 Oct;
32(1):46-53.
PMID: 34663079
Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. Fatigue is one...